Dr. Buynak is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 University Dr Ste 106
Valparaiso, IN 46383- Is this information wrong?
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1995 - 1998
Harvard Medical SchoolClass of 1995
Certifications & Licensure
IL State Medical License 2005 - 2026
OH State Medical License 2023 - 2025
IN State Medical License 1998 - 2025
TX State Medical License 2023 - 2024
AL State Medical License 2023 - 2024
WI State Medical License 2023 - 2023
FL State Medical License 2012 - 2016- American Board of Internal Medicine Internal Medicine
- Join now to see all
Awards, Honors, & Recognition
- Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2014-2016
Clinical Trials
- A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain Start of enrollment: 2014 Jul 01
- Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM Start of enrollment: 2015 Sep 01
- Effects of the GOLO for Life System Diet With and Without GOLO Release Supplement on Glycemic Control and Insulin Resistance Start of enrollment: 2019 Oct 01
Publications & Presentations
PubMed
- 1 citationsShort article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.Stefan Zeuzem, Parvez S. Mantry, Vicente Soriano, Robert Buynak, Jean-François Dufour, Paul J. Pockros, David Wright, Peter W Angus, Maria Buti, Jerry O. Stern, Werner...> ;European Journal of Gastroenterology & Hepatology. 2016 Aug 1
- Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.Donald M. Jensen, Tarik Asselah, Douglas T. Dieterich, Graham R. Foster, Mark S. Sulkowski, Stefan Zeuzem, Parvez S. Mantry, Eric M. Yoshida, Christophe Moreno, Denis ...> ;Annals of Hepatology. 2016 May 1
- 43 citationsLong-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open...Robert Buynak, Stephen A. Rappaport, Kevin Rod, Pierre Arsenault, Fabian Heisig, C. Rauschkolb, Mila Etropolski> ;Clinical Therapeutics. 2015 Nov 1
- Join now to see all
Hospital Affiliations
- Northwest Health -PorterValparaiso, Indiana
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
